Meet our SPARK Fellows
Introducing Cohort 8
Achim Klug, PhD
Hearing Restoration for Age-Related Hearing Loss
Email Address:achim.klug@cuanschutz.edu
Hearing Restoration for Age-Related Hearing Loss
Our technology addresses age-related central hearing loss, a condition affecting the auditory brain and making it difficult for individuals to follow conversations in noisy environments. We propose a treatment combining a long-approved FDA drug with an engineered sound file to restore auditory brain circuits. This one-month therapy aims to benefit over 100 million people in North America, Europe, and Japan. We will demonstrate the treatment's efficacy, explore regulatory pathways, and prepare for commercialization with NIH and SPARK funding. The project includes clinical trials and customer discovery, aiming for successful licensing or the startup of a new company.
Learn more about Dr. KlugCohort 7
Cohort 6
Achim Klug, PhD
Hearing Restoration for Age-Related Hearing Loss
Email Address:achim.klug@cuanschutz.edu
Hearing Restoration for Age-Related Hearing Loss
Our technology addresses age-related central hearing loss, a condition affecting the auditory brain and making it difficult for individuals to follow conversations in noisy environments. We propose a treatment combining a long-approved FDA drug with an engineered sound file to restore auditory brain circuits. This one-month therapy aims to benefit over 100 million people in North America, Europe, and Japan. We will demonstrate the treatment's efficacy, explore regulatory pathways, and prepare for commercialization with NIH and SPARK funding. The project includes clinical trials and customer discovery, aiming for successful licensing or the startup of a new company.
Learn more about Dr. KlugCohort 5
Achim Klug, PhD
Hearing Restoration for Age-Related Hearing Loss
Email Address:achim.klug@cuanschutz.edu
Hearing Restoration for Age-Related Hearing Loss
Our technology addresses age-related central hearing loss, a condition affecting the auditory brain and making it difficult for individuals to follow conversations in noisy environments. We propose a treatment combining a long-approved FDA drug with an engineered sound file to restore auditory brain circuits. This one-month therapy aims to benefit over 100 million people in North America, Europe, and Japan. We will demonstrate the treatment's efficacy, explore regulatory pathways, and prepare for commercialization with NIH and SPARK funding. The project includes clinical trials and customer discovery, aiming for successful licensing or the startup of a new company.
Learn more about Dr. Klug